Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:N Engl J Med
Main Authors: Sadoff, Jerald, Le Gars, Mathieu, Shukarev, Georgi, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne M., Stoop, Jeroen, Tete, Sarah, Van Damme, Wim, Leroux-Roels, Isabel, Berghmans, Pieter-Jan, Kimmel, Murray, Van Damme, Pierre, de Hoon, Jan, Smith, William, Stephenson, Kathryn E., De Rosa, Stephen C., Cohen, Kristen W., McElrath, M. Juliana, Cormier, Emmanuel, Scheper, Gert, Barouch, Dan H., Hendriks, Jenny, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke
Format: Artigo
Jezik:Inglês
Izdano: Massachusetts Medical Society 2021
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7821985/
https://ncbi.nlm.nih.gov/pubmed/33440088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2034201
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki